Abnylon

BHD. (AB Nylon) is a privately held company established in November 2016 solely for the manufacturing of advanced wound (acute and chronic wounds) and burn care products which address the unmet cost effectiveness related to advance wound management globally. We are building upon a legacy medical nano technology innovation to further improve patient outcomes and committed to transform the expensive wound treatment by reducing the costs to a fraction for all. Our next-generation line of advance wound and burn care products will touch the lives of millions every day and also help the health care professionals to alleviate the patients' suffering. or decades the emergence of multi drug resistant microbes, hospital and community acquired infections are often more threatening to the patient and cost the healthcare system more than the treatment for the original syndrome or injury for which the patient was treated. These antibiotic resistance microbes and the concentration of pharmaceutical research in other markets have combined to open up a major opportunity in a growing $10 billion wound care market for AB Nylon which has been assigned with Omni Shield® technology/patent. The wound care market includes both acute or chronic segments. Acute wounds typically result from trauma or surgery, and chronic wound typically develops for many pathological reason such as aging, blood supply insufficiencies, or suppressed immune systems. AB Nylon will provide products for both the acute and chronic markets.AB Nylon's product platform is made up of single layer and multi layer dressings that comes in an array of different sizes and configurations. Our products are configured to satisfy customer needs which includes contact dressings, island dressings, burn dressings and negative pressure dressings.